CRWENewswire, Stocks to Watch. Threshold Pharmaceuticals Inc - THLD - reported that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012.
Categorie: Video blog
Etichete: merck, thld, thld, threshold, threshold pharmaceuticals
Raporteaza - consideri acest film nepotrivit? Raporteaza aici